Showing results (111-120 of 168) with videos related to

Sort By:
Pageof 17
Oncotarget|November 22, 2017
Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenograftsIrene Brana, Nhu-An Pham, Lucia Kim, et al.
British Journal of Cancer|July 22, 2022
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancerMark K Doherty, Vincent C Tam, Mairéad G McNamara, et al.
International Journal of Radiation Oncology, Biology, Physics|August 17, 2010
Cognitive functioning after radiotherapy or chemoradiotherapy for head-and-neck cancerHui K Gan, Lori J Bernstein, Jennifer Brown, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 5, 2022
Interobserver and intraobserver variability of RECIST assessment in ovarian cancerMichael Krasovitsky, Yeh Chen Lee, Hao-Wen Sim, et al.
American Journal of Clinical Oncology|January 1, 2010
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancerSrikala S Sridhar, Sebastien J Hotte, Joseph L Chin, et al.
Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.
British Journal of Cancer|May 21, 2019
A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trialGrainne M O'Kane, Shereen Ezzat, Anthony M Joshua, et al.
American Journal of Obstetrics and Gynecology|June 26, 2021
Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferencesAinhoa Madariaga, Gita Bhat, Michelle K Wilson, et al.
JNCI Cancer Spectrum|April 28, 2020
Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic IndexDaphne Day, Christina Guo, Yada Kanjanapan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 28, 2023
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancersEduardo Gonzalez-Ochoa, Michael Milosevic, Bradley Corr, et al.
Pageof 17